» Articles » PMID: 20825389

Stereo-selective Metabolism of Methadone by Human Liver Microsomes and CDNA-expressed Cytochrome P450s: a Reconciliation

Overview
Specialties Pharmacology
Toxicology
Date 2010 Sep 10
PMID 20825389
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

In vitro metabolism of methadone was investigated in cytochrome P450 (CYP) supersomes and phenotyped human liver microsomes (HLMs) to reconcile past findings on CYP involvement in stereo-selective metabolism of methadone. Racaemic methadone was used for incubations; (R)- and (S)-methadone turnover and (R)- and (S)-EDDP formation were determined using chiral liquid chromatography-tandem mass spectrometry. CYP supersome activity for methadone use and EDDP formation ranked CYP2B6 > 3A4 > 2C19 > 2D6 > 2C18, 3A7 > 2C8, 2C9, 3A5. After abundance scaling, CYP3A4, 2B6 and 2C19 accounted for 63-74, 12-32 and 1. 4-14% of respective activity. CYP2B6, 2D6 and 2C18 demonstrated a preference for (S)-EDDP formation; CYP2C19, 3A7 and 2C8 for (R)-EDDP; 3A4 none. Correlation analysis with 15 HLMs supported the involvement of CYP2B6 and 3A. The significant correlation of S/R ratio with CYP2B6 activity confirmed its stereo-selectivity. CYP2C19 and 2D6 inhibitors and monoclonal antibody (mAb) did not inhibit EDDP formation in HLM. Chemical and mAb inhibition of CYP3A in high 3A activity HLM reduced EDDP formation by 60-85%; inhibition of CYP2B6 in 2B6 high-activity HLM reduced (S)-EDDP formation by 80% and (R)-EDDP formation by 55%. Inhibition changed methadone metabolism in a stereo-selective manner. When CYP3A was inhibited, 2B6 mediated (S)-EDDP formation predominated; S/R stereo-selectivity increased. When 2B6 was inhibited (S)-EDDP formation fell and stereo-selectivity decreased. The results confirmed the primary roles of CYPs 3A4 and 2B6 in methadone metabolism; CYP2C8 and 2C9 did not appear involved; 2C19 and 2D6 have minimal roles. CYP2B6 is the primary determinant of stereo-selective metabolism; stereo-selective inhibition might play a role in varied plasma concentrations of the two enantiomers.

Citing Articles

Opioid use disorder in pediatric populations: considerations for perioperative pain management and precision opioid analgesia.

Chen Y, Xenitidis A, Hoffmann P, Matthews L, Padmanabhan S, Aravindan L Expert Rev Clin Pharmacol. 2024; 17(5-6):455-465.

PMID: 38626303 PMC: 11116045. DOI: 10.1080/17512433.2024.2343915.


Natural Products Inhibition of Cytochrome P450 2B6 Activity and Methadone Metabolism.

Wang P, Yang Y, Patel V, Neiner A, Kharasch E Drug Metab Dispos. 2023; 52(3):252-265.

PMID: 38135504 PMC: 10877711. DOI: 10.1124/dmd.123.001578.


Identifying Clinically Relevant Drug-Drug Interactions With Methadone and Buprenorphine: A Translational Approach to Signal Detection.

Miano T, Wang L, Leonard C, Brensinger C, Acton E, Dawwas G Clin Pharmacol Ther. 2022; 112(5):1120-1129.

PMID: 35881659 PMC: 10015595. DOI: 10.1002/cpt.2717.


In vitro-in silico-based prediction of inter-individual and inter-ethnic variations in the dose-dependent cardiotoxicity of R- and S-methadone in humans.

Shi M, Dong Y, Bouwmeester H, Rietjens I, Strikwold M Arch Toxicol. 2022; 96(8):2361-2380.

PMID: 35604418 PMC: 9217890. DOI: 10.1007/s00204-022-03309-y.


The Risk of Ventricular Dysrhythmia or Sudden Death in Patients Receiving Serotonin Reuptake Inhibitors With Methadone: A Population-Based Study.

Antoniou T, McCormack D, Tadrous M, Juurlink D, Gomes T Front Pharmacol. 2022; 13:861953.

PMID: 35517813 PMC: 9065276. DOI: 10.3389/fphar.2022.861953.


References
1.
Totah R, Allen K, Sheffels P, Whittington D, Kharasch E . Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther. 2007; 321(1):389-99. DOI: 10.1124/jpet.106.117580. View

2.
Prost F, Thormann W . Capillary electrophoresis to assess drug metabolism induced in vitro using single CYP450 enzymes (Supersomes): application to the chiral metabolism of mephenytoin and methadone. Electrophoresis. 2003; 24(15):2577-87. DOI: 10.1002/elps.200305493. View

3.
Kharasch E, Bedynek P, Park S, Whittington D, Walker A, Hoffer C . Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. Clin Pharmacol Ther. 2009; 84(4):497-505. PMC: 3583342. DOI: 10.1038/clpt.2008.104. View

4.
Moody D, Alburges M, Parker R, Collins J, Strong J . The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone. Drug Metab Dispos. 1998; 25(12):1347-53. View

5.
Gerber J, Rhodes R, Gal J . Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality. 2003; 16(1):36-44. DOI: 10.1002/chir.10303. View